FCA
TVRD

FinTrust Capital Advisors’s Tvardi Therapeutics TVRD Stock Holding History

FinTrust Capital Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$81 Hold
7
– – ﹤0.01% 1352
2024
Q2 		$68 Hold
7
– – ﹤0.01% 1356
2024
Q1 		$237 Hold
7
– – ﹤0.01% 1233
2023
Q4 		$194 Hold
7
– – ﹤0.01% 1217
2023
Q3 		$437 Hold
7
– – ﹤0.01% 1173
2023
Q2 		$2.79K Hold
7
– – ﹤0.01% 962
2023
Q1 		$2.79K Hold
7
– – ﹤0.01% 955
2022
Q4 		$2.79K Hold
7
– – ﹤0.01% 953
2022
Q3 		$3K Hold
7
– – ﹤0.01% 1105
2022
Q2 		$3K Hold
7
– – ﹤0.01% 1116
2022
Q1 		$3K Hold
7
– – ﹤0.01% 1132
2021
Q4 		$3K Buy
+7
New +$3.52K ﹤0.01% 1086

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FinTrust Capital Advisors's TVRD Position: Q3 2024 in Review

FinTrust Capital Advisors held its Tvardi Therapeutics (TVRD) position steady in Q3 2024 at 7 shares worth $81. The position accounts for ﹤0.01% of the portfolio, ranked #1352.

FinTrust Capital Advisors first reported a position in TVRD in Q4 2021 and has held it in 12 quarters since. The position peaked at $3K in Q3 2022. 69 funds tracked by Wall St. Rank hold TVRD as of Q3 2024.

  • FinTrust Capital Advisors held 7 shares of Tvardi Therapeutics worth $81 as of Q3 2024.
  • FinTrust Capital Advisors left its Tvardi Therapeutics share count unchanged in Q3 2024.
  • Tvardi Therapeutics made up ﹤0.01% of FinTrust Capital Advisors's portfolio in Q3 2024, its #1352 holding.
  • FinTrust Capital Advisors first reported a position in Tvardi Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • FinTrust Capital Advisors's Tvardi Therapeutics position peaked at $3K in Q3 2022.
  • 69 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2024.

Based on FinTrust Capital Advisors's 13F filing for Q3 2024, filed 11 Oct 2024.